New Copaxone® (glatiramer acetate) formulation launched in UK

Posted in News Review on 14th Aug 2015

ACNRJA15-31cTeva UK Limited (“Teva”) has launched Copaxone® 40mg/ml three-times weekly injection. Copaxone® 20mg/ml is currently approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). With this new formulation, patients will only have to inject themselves three times per week – compared to daily injections with the existing formulation.

Approval was granted in December 2014 and was based on the findings from Teva’s Phase III Glatiramer Acetate Low-Frequency Administration (GALA) study, which involved over 1,400 patients. Results demonstrated that patients dosed three-times weekly with Copaxone® 40 mg/ml experienced significantly reduced relapse rates compared to placebo at 12 months, with a safety and tolerability profile similar to that of Copaxone® 20mg/ml daily.

Dr Ewan Walters, Teva UK’s Medical Director, said: “Teva has been committed to the pursuit of MS research, and the development of Copaxone®, for more than 20 years. We are proud to be able to bring to patients in the UK the option of this new, three-times weekly Copaxone® 40 mg/ml formulation which we believe will offer patients and their healthcare professionals flexibility in choosing a dosing regimen that works best for them.”

Copaxone has been available in the UK since 2000. The three-times weekly 40 mg/ml formulation gives patients a convenient treatment option. Clinical studies have shown three-times weekly Copaxone® can maintain the benefits of relapse reduction of the once-a-day formulation, with 57 percent fewer injections.

ACNR 2015;15(3):31.   Online 30 /07/15

Download this Article

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

See a sample email newsletter here
This website is for medical professionals only.